<DOC>
	<DOCNO>NCT00800709</DOCNO>
	<brief_summary>In AD , tau protein abnormally hyperphosphorylated . Significant change hyperphosphorylated tau level CSF find AD patient . It show vitro memantine reverse abnormal hyperphosphorylation tau hippocampal neuron rat . A statistically significant reduction CSF phosphorylated tau preliminary 1-year follow-up observe , median 126 ( interquartile range 107-153 ) 108 ( 88-133 ) ng/l ( p = 0.018 ) . No statistically significant difference total tau Aβ42 found ( Gunnarsson MD , 2007 ) . FDG-PET unique ability estimate local cerebral metabolic rate glucose consumption , thus provide information distribution neuronal death synapse dysfunction AD vivo ( Herholz K. 2003 ) . Synaptic dysfunction loss induce reduction neuronal energy demand result decrease glucose metabolism . Hypometabolism AD think reflect loss synaptic activity density ( Herholz K. 2003 ; Mielke R , et al . 1998 ) . Another biological marker inflammatory factor APOEε4 also play part onset AD ( Glodzik-Sobanska L , 2007 ) .</brief_summary>
	<brief_title>Memantine Changes Biological Markers Brain PET Imaging Alzheimer 's Disease</brief_title>
	<detailed_description>1 . To investigate effect daily dose memantine 24 week versus placebo biological marker subject Alzheimer 's disease . 2 . To investigate effect daily dose memantine 24 week versus placebo 18 [ F ] -FDG-PET brain subject Alzheimer 's disease . 3 . To investigate effect daily dose memantine 24 week versus placebo cognitive function subject Alzheimer 's disease . 4 . To investigate effect daily dose memantine 24 week versus placebo measure behavior activity daily live subject Alzheimer 's disease . 5 . To investigate effect daily dose memantine 24 week versus placebo short term memory .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Written inform consent 2 . Clinical diagnosis Alzheimer 's disease meet DSMIV criterion . 3 . Subject moderate severe Alzheimer 's disease define MMSE score 4 20 inclusive screening . 4 . Hachinski Ischemia Score &lt; 4 screening . 5 . Age ≥50 ≤90 year . 6 . Availability responsible steady caregiver ensure treatment compliance provide information assessment . 1 . Severe renal impairment . 2 . History seizures 3 . Systolic blood pressure &gt; 160 &lt; 90 mmHg diastolic blood pressure &gt; 95 &lt; 60 mmHg time screen . 4 . Diagnosis concomitant life threaten illness .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>tau protein</keyword>
	<keyword>PET</keyword>
	<keyword>Memantine</keyword>
</DOC>